Abstract |
2'-Beta-fluoro-2',3'-dideoxyadenosine (F-ddA, lodenosine) is an experimental anti-AIDS drug currently being evaluated in a Phase I clinical trial. A simple and specific HPLC method with UV detection, suitable for use in clinical studies, has been developed to determine both F-ddA and its deaminated catabolite, 2'-beta-fluoro-2',3'-dideoxyinosine (F-ddI) in human plasma. After inactivation of plasma HIV by 0.5% Triton X-100, the compounds of interest are isolated and concentrated using solid-phase extraction. Processed samples are separated by use of a pH 4.8 buffered methanol gradient on a reversed-phase phenyl column. The method has a linear range of 0.05-5 microg/ml (0.2-20 microM) and intra-assay precision is better than 8%. Analyte recovery is quantitative and plasma protein binding is minimal. In addition, drug and metabolite levels measured in Triton-treated human plasma remain stable for at least 5 months when samples are stored frozen without further treatment. Compound concentrations determined after samples are processed and then frozen for up to 1 month before analysis are also unchanged.
|
Authors | J S Roth, H Ford Jr, M Tanaka, H Mitsuya, J A Kelley |
Journal | Journal of chromatography. B, Biomedical sciences and applications
(J Chromatogr B Biomed Sci Appl)
Vol. 712
Issue 1-2
Pg. 199-210
(Aug 07 1998)
ISSN: 1387-2273 [Print] Netherlands |
PMID | 9698243
(Publication Type: Journal Article)
|
Chemical References |
- Anti-HIV Agents
- Blood Proteins
- lodenosine
- Dideoxyadenosine
|
Topics |
- Acquired Immunodeficiency Syndrome
(blood, virology)
- Anti-HIV Agents
(blood, metabolism)
- Blood Proteins
(metabolism)
- Chromatography, High Pressure Liquid
- Dideoxyadenosine
(analogs & derivatives, blood, metabolism)
- Drug Stability
- HIV
(drug effects, growth & development)
- HIV Seropositivity
(blood, virology)
- Humans
- Protein Binding
- Reproducibility of Results
- Spectrophotometry, Ultraviolet
|